CytoMed Therapeutics Ltd. (GDTC): Price and Financial Metrics
GDTC Price/Volume Stats
Current price | $2.17 | 52-week high | $9.25 |
Prev. close | $2.24 | 52-week low | $1.92 |
Day low | $2.17 | Volume | 2,900 |
Day high | $2.17 | Avg. volume | 36,233 |
50-day MA | $2.64 | Dividend yield | N/A |
200-day MA | $3.46 | Market Cap | 23.74M |
GDTC Stock Price Chart Interactive Chart >
Latest GDTC News From Around the Web
Below are the latest news stories about CYTOMED THERAPEUTICS LTD that investors may wish to consider to help them evaluate GDTC as an investment opportunity.
One CytoMed Therapeutics Insider Raised Stake By 46% In Previous YearFrom what we can see, insiders were net buyers in CytoMed Therapeutics Limited's ( NASDAQ:GDTC ) during the past 12... |
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell TechnologyCytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., |
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate UpdateCytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results and provided clinical and corporate updates. |
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor ConferenceCytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City. |
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based TechnologySINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies ... |
GDTC Price Returns
1-mo | 8.50% |
3-mo | -55.71% |
6-mo | -38.00% |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | -55.71% |
2023 | N/A |
2022 | N/A |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...